Kuros Biosciences AG (CSBTF)
USD 32.4
(3.09%)
USD 32.4
(3.09%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 28.47 Million CHF | 158.0% |
| 2022 | 10.76 Million CHF | 6.98% |
| 2021 | 10.06 Million CHF | 502.39% |
| 2020 | 1.67 Million CHF | 2215.19% |
| 2019 | -79 Thousand CHF | 97.08% |
| 2018 | -2.7 Million CHF | 2.53% |
| 2017 | -2.77 Million CHF | 4.15% |
| 2016 | -2.89 Million CHF | -149.91% |
| 2015 | 5.79 Million CHF | 163.64% |
| 2014 | -9.1 Million CHF | 23.83% |
| 2013 | -11.94 Million CHF | -1186.27% |
| 2012 | 1.1 Million CHF | -29.98% |
| 2011 | 1.57 Million CHF | -92.97% |
| 2010 | 22.34 Million CHF | 145.38% |
| 2009 | 9.1 Million CHF | -53.82% |
| 2008 | 19.72 Million CHF | 6.71% |
| 2007 | 18.48 Million CHF | 276.43% |
| 2006 | -10.47 Million CHF | -340.39% |
| 2005 | 4.35 Million CHF | 5.98% |
| 2004 | 4.11 Million CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 14.18 Million CHF | -18.6% |
| 2024 Q2 | 14.18 Million CHF | 0.0% |
| 2023 FY | 27.78 Million CHF | 158.0% |
| 2023 Q2 | 10.36 Million CHF | 145.7% |
| 2023 Q1 | 4.21 Million CHF | -25.24% |
| 2023 Q4 | 17.42 Million CHF | 141.35% |
| 2023 Q3 | 7.21 Million CHF | -30.31% |
| 2022 Q1 | 3 Million CHF | 11.79% |
| 2022 FY | 10.76 Million CHF | 6.98% |
| 2022 Q4 | 5.64 Million CHF | 257.41% |
| 2022 Q3 | 1.57 Million CHF | -80.78% |
| 2022 Q2 | 8.2 Million CHF | 172.77% |
| 2021 FY | 10.06 Million CHF | 502.39% |
| 2021 Q3 | -1.05 Million CHF | -115.3% |
| 2021 Q4 | 2.69 Million CHF | 355.41% |
| 2021 Q2 | 6.88 Million CHF | 91.73% |
| 2021 Q1 | 3.59 Million CHF | 551.89% |
| 2020 Q3 | 785 Thousand CHF | 486.7% |
| 2020 Q4 | -795 Thousand CHF | -201.27% |
| 2020 Q2 | -203 Thousand CHF | -501.98% |
| 2020 FY | 1.67 Million CHF | 2215.19% |
| 2020 Q1 | 50.5 Thousand CHF | 244.29% |
| 2019 Q3 | -215.49 Thousand CHF | 64.08% |
| 2019 FY | -79 Thousand CHF | 97.08% |
| 2019 Q4 | -35 Thousand CHF | 83.76% |
| 2019 Q2 | -600 Thousand CHF | -255.44% |
| 2019 Q1 | 386 Thousand CHF | 113.85% |
| 2018 Q4 | 180.5 Thousand CHF | 0.0% |
| 2018 Q2 | 129 Thousand CHF | 0.0% |
| 2018 Q3 | 180.5 Thousand CHF | 39.92% |
| 2018 FY | -2.7 Million CHF | 2.53% |
| 2018 Q1 | 129 Thousand CHF | 105.77% |
| 2017 Q1 | 267 Thousand CHF | 119.87% |
| 2017 Q2 | 267 Thousand CHF | 0.0% |
| 2017 Q3 | -2.23 Million CHF | -937.08% |
| 2017 Q4 | -2.23 Million CHF | 0.0% |
| 2017 FY | -2.77 Million CHF | 4.15% |
| 2016 Q1 | -2.08 Million CHF | -1550.79% |
| 2016 Q2 | -2.08 Million CHF | 0.0% |
| 2016 FY | -2.89 Million CHF | -149.91% |
| 2016 Q3 | -1.34 Million CHF | 35.38% |
| 2016 Q4 | -1.34 Million CHF | 0.0% |
| 2015 Q1 | -59.5 Thousand CHF | 0.0% |
| 2015 Q4 | -126 Thousand CHF | 0.0% |
| 2015 FY | 5.79 Million CHF | 163.64% |
| 2015 Q2 | -59.5 Thousand CHF | 0.0% |
| 2015 Q3 | -126 Thousand CHF | -111.76% |
| 2014 FY | -9.1 Million CHF | 23.83% |
| 2013 Q4 | -12.69 Million CHF | -5179.6% |
| 2013 Q2 | 250 Thousand CHF | 0.0% |
| 2013 Q1 | 250 Thousand CHF | 0.0% |
| 2013 Q3 | 250 Thousand CHF | 0.0% |
| 2013 FY | -11.94 Million CHF | -1186.27% |
| 2012 Q2 | 350 Thousand CHF | 40.0% |
| 2012 Q4 | 250 Thousand CHF | 0.0% |
| 2012 Q3 | 250 Thousand CHF | -28.57% |
| 2012 Q1 | 250 Thousand CHF | 0.0% |
| 2012 FY | 1.1 Million CHF | -29.98% |
| 2011 Q4 | 250 Thousand CHF | -24.7% |
| 2011 Q2 | 389 Thousand CHF | -35.17% |
| 2011 Q1 | 600 Thousand CHF | -4.76% |
| 2011 Q3 | 332 Thousand CHF | -14.65% |
| 2011 FY | 1.57 Million CHF | -92.97% |
| 2010 Q1 | 250 Thousand CHF | -65.03% |
| 2010 FY | 22.34 Million CHF | 145.38% |
| 2010 Q4 | 630 Thousand CHF | 110.0% |
| 2010 Q3 | 300 Thousand CHF | -98.58% |
| 2010 Q2 | 21.16 Million CHF | 8367.6% |
| 2009 Q4 | 715 Thousand CHF | -60.67% |
| 2009 FY | 9.1 Million CHF | -53.82% |
| 2009 Q1 | 250 Thousand CHF | 0.0% |
| 2009 Q2 | 6.32 Million CHF | 2430.0% |
| 2009 Q3 | 1.81 Million CHF | -71.26% |
| 2008 FY | 19.72 Million CHF | 6.71% |
| 2007 FY | 18.48 Million CHF | 276.43% |
| 2006 FY | -10.47 Million CHF | -340.39% |
| 2005 FY | 4.35 Million CHF | 5.98% |
| 2004 FY | 4.11 Million CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Agentix Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 1167422.673% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -5801.545% |
| Biomind Labs Inc. | -15.42 Thousand USD | 184688.952% |
| ContraFect Corporation | -154 Thousand USD | 18587.662% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -6841.353% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.623% |
| CytoDyn Inc. | -29 Thousand USD | 98275.862% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -143.217% |
| GB Sciences, Inc. | -624.00 USD | 4562760.256% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 210.361% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 59096.249% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 83470.425% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -16025.396% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 23014.101% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 76.096% |
| SQZ Biotechnologies Company | 9.79 Million USD | -190.698% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -45654.186% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -89.819% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -43216.395% |
| Mesoblast Limited | -35.16 Million USD | 180.957% |
| Marizyme, Inc. | 457.7 Thousand USD | -6120.423% |
| Genus plc | 178.7 Million USD | 84.068% |
| Pharming Group N.V. | 220.1 Million USD | 87.065% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 258927.273% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -36990.45% |
| IMV Inc. | -962.29 Thousand USD | 3058.647% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 7447.336% |
| MultiCell Technologies, Inc. | 49.32 USD | -57726988.402% |
| ONE Bio Corp. | 20.12 Million USD | -41.468% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 29.291% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -0.764% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 2594.017% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -40572.857% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 575039.418% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -20164.057% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 33195.039% |
| Enzolytics Inc. | 30.7 Thousand USD | -92615.253% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 97.432% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 5633.615% |
| Genscript Biotech Corporation | 409.55 Million USD | 93.048% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -917727.208% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 321588.257% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 34055.086% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 57042.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -2781.736% |
| EV Biologics, Inc. | 48.9 Thousand USD | -58122.904% |
| Q BioMed Inc. | -8988.00 USD | 316866.8% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -196.233% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 35.815% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | -84.579% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 29296.534% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 13688080.769% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -4511.555% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 4618.217% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 240666.117% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -16025.396% |
| Affymax, Inc. | 1.35 Million USD | -1997.863% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -517.86% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | -8285.00 USD | 343745.142% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -6226.284% |
| SYBLEU INC | 11.69 Thousand USD | -243325.103% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 9010.916% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 7732.976% |
| Neutra Corp. | 14.33 Thousand USD | -198511.789% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 34820.732% |
| PureTech Health plc | -1.6 Million USD | 1876.107% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 2943.585% |
| IXICO plc | 3.27 Million USD | -770.673% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 4202.45% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 1689.671% |
| CSL Limited | 7.7 Billion USD | 99.63% |
| Cellectis S.A. | 18 Thousand USD | -158072.222% |